We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Introducing deCODEme Cardio™ and deCODEme Cancer™
Product News

Introducing deCODEme Cardio™ and deCODEme Cancer™

Introducing deCODEme Cardio™ and deCODEme Cancer™
Product News

Introducing deCODEme Cardio™ and deCODEme Cancer™


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Introducing deCODEme Cardio™ and deCODEme Cancer™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Through deCODEme™, deCODE genetics has announced the launch of the first focused genetic scans for assessing personal risk of several major cardiovascular diseases and common cancers.

deCODEme Cardio™, which detects genetic risk factors for heart attack, stroke and atrial fibrillation, peripheral artery disease (PAD), and several other conditions, is offered at an introductory price of $195.

deCODEme Cancer measures genetic risk factors for prostate, lung, bladder, skin and colorectal cancers, as well as the common form of breast cancer, at an introductory price of $225. Both can be ordered as a bundle for $350. Detailed information on what the scans measure and how to order can be found at www.decodeme.com/cancer.

The scans - deCODEme Cardio™ and deCODEme Cancer™ - build on deCODE's global leadership in the discovery of common variations in the sequence of the human genome conferring increased risk of common diseases. The scans are based on assays custom designed by deCODE scientists to detect the single-letter genetic variations (called SNPs) with the biggest impact on disease risk. These are SNPs validated in large-scale studies by deCODE as well as leading academic research institutions.

DNA Analysis is conducted in deCODE's own CLIA-registered laboratory, one of the largest genotyping facilities in the world. Subscribers have access to genetic counseling. Many deCODE customers have already employed the results of deCODEme and the company's range of DNA-based risk assessment tests to improve and protect their health.

deCODEme Cardio™ measures 8 SNPs associated with the risk of heart attack, intracranical and abdominal aortic aneurysm, stroke and atrial fibrillation, peripheral arterial disease (PAD) and venous thromboempolism. deCODEme Cancer™ measures 29 SNPs associated with risk of prostate, lung, bladder and colorectal cancers, as well as basal cell carcinoma and the common form of breast cancer. Based upon which versions of these SNPs they carry, subscribers will receive a secure online profile presenting their results.

Results are presented both in terms of relative risk compared to the general population, as well as absolute lifetime risk, which is the percentage likelihood that an individual will develop a disease in their lifetime, which is their relative risk multiplied by the average lifetime risk in the population.
Advertisement